ArticleMolecular medicine (Cambridge, Mass.)2025
Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies.
Romana Nesnadna et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it